Cargando…
Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology—A PROLONG-II Substudy
In patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF), three months of optimal therapy are recommended before considering a primary preventive implantable cardioverter-defibrillator (ICD). It is unclear which patients benefit from a prolonged waiting period under prot...
Autores principales: | Mueller-Leisse, Johanna, Brunn, Johanna, Zormpas, Christos, Hohmann, Stephan, Hillmann, Henrike Aenne Katrin, Eiringhaus, Jörg, Bauersachs, Johann, Veltmann, Christian, Duncker, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914738/ https://www.ncbi.nlm.nih.gov/pubmed/35271182 http://dx.doi.org/10.3390/s22052037 |
Ejemplares similares
-
Extended follow‐up after wearable cardioverter‐defibrillator period: the PROLONG‐II study
por: Mueller‐Leisse, Johanna, et al.
Publicado: (2021) -
Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction
por: Hillmann, Henrike Aenne Katrin, et al.
Publicado: (2021) -
Changes in eligibility for a subcutaneous cardioverter-defibrillator after implantation of a left ventricular assist device–A prospective analysis
por: Zormpas, Christos, et al.
Publicado: (2023) -
Premature end of service of implantable cardioverter-defibrillator by magnetic interference with left-ventricular assist device
por: Eiringhaus, Jörg, et al.
Publicado: (2021) -
Eligibility for subcutaneous implantable cardioverter-defibrillator in patients with left ventricular assist device
por: Zormpas, Christos, et al.
Publicado: (2020)